Boston Scientific (NYSE:BSX) Issues FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 3.280-3.320 for the period, compared to the consensus earnings per share estimate of 3.360. The company issued revenue guidance of $21.2 billion-$21.4 billion, compared to the consensus revenue estimate of $21.6 billion. Boston Scientific also updated its Q3 2026 guidance to 0.800-0.820 EPS.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded down $0.89 during midday trading on Thursday, hitting $45.15. The company had a trading volume of 8,721,671 shares, compared to its average volume of 18,262,002. The company has a fifty day moving average of $46.57 and a two-hundred day moving average of $62.73. The company has a market cap of $67.11 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 0.88 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific has a 12-month low of $42.20 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.37 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts expect that Boston Scientific will post 3.35 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Barclays reduced their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Leerink Partners set a $60.00 price objective on Boston Scientific in a research report on Thursday. Needham & Company LLC dropped their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Oppenheimer decreased their price target on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $71.96.

Insider Buying and Selling

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q2 results exceeded expectations: Boston Scientific reported adjusted EPS of $0.86 versus the $0.83 consensus estimate, while revenue rose 7.5% year over year to $5.442 billion, above the $5.37 billion forecast. Cardiovascular sales increased 8.3%, with particularly strong growth in APAC and LACA. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: Growth and cost initiatives remain longer-term catalysts: Management highlighted broad portfolio growth, new product launches, cost savings from its restructuring program, FDA clearance for the TruSelect 2.6 Microcatheter, and the company’s investment in MiRus and its transcatheter aortic valve replacement business. The restructuring targets approximately $500 million in annual savings, although it may cost $700 million to $800 million through 2029. Boston Scientific Q2 earnings call highlights
• Neutral Sentiment: Sales outlook was raised, but profit expectations were reduced: Boston Scientific now expects full-year reported sales growth of approximately 5.5% to 6.5%, but cut adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41. Third-quarter EPS guidance of $0.80-$0.82 and revenue guidance of $5.2-$5.3 billion also trail consensus estimates of $0.84 and $5.4 billion, respectively. Boston Scientific trims annual profit forecast
• Negative Sentiment: Watchman and EP weakness is resetting expectations: Softer demand for the Watchman device, competitive pressure and weaker trends in EP are forcing management to take a more cautious view of growth. Analysts have responded by cutting valuation targets, including UBS’s reduction to $74 from $95, BTIG’s reduction to $60 from $65, and a fair-value cut to $72.25 from $75. BSX Q2 earnings call highlights WATCHMAN and EP pressure
• Negative Sentiment: Restructuring and recall add execution risk: The multi-year restructuring will involve headcount reductions and significant upfront costs, while a recall of the Rapid Refill Continuous Injection System creates an additional operational and reputational concern. Boston Scientific expects headcount reductions

Institutional Trading of Boston Scientific

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC lifted its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. Kitching Partners LLC acquired a new position in Boston Scientific in the 4th quarter worth $202,000. DV Equities LLC bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $197,000. Sunbelt Securities Inc. lifted its position in shares of Boston Scientific by 33.0% in the fourth quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider’s stock valued at $135,000 after buying an additional 350 shares during the last quarter. Finally, Prosperity Bancshares Inc acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $111,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.